<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143894</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00110211</org_study_id>
    <secondary_id>J16135</secondary_id>
    <nct_id>NCT03143894</nct_id>
  </id_info>
  <brief_title>Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation</brief_title>
  <official_title>Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Under Armour, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the preliminary efficacy of transcranial direct current stimulation&#xD;
      (tDCS) to improve fatigue and cognition in women with a history of breast cancer and&#xD;
      persistent fatigue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue and cognitive dysfunction are commonly reported symptoms associated with impaired&#xD;
      quality of life and productivity in breast cancer survivors. Transcranial direct current&#xD;
      stimulation (tDCS) has been shown to improve both fatigue and cognition. Here tDCS will be&#xD;
      used in a randomized, sham-controlled, double-blind, cross-over trial in women who have&#xD;
      finished treatment of breast cancer and who report persistent fatigue.&#xD;
&#xD;
      Participants will complete measures of fatigue and cognition before and after five&#xD;
      consecutive days of active or sham tDCS then complete questionnaires by phone one week later.&#xD;
      Participants will return about one month later for another five days of participation,&#xD;
      followed by another brief study phone call the following week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual (inability to enroll participants)&#xD;
  </why_stopped>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, sham-controlled, double-blind, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change on Paced Auditory Serial Attention Test (PASAT)</measure>
    <time_frame>Baseline and Day 5</time_frame>
    <description>Change in auditory working memory as measured by the PASAT prior to and following the intervention. PASAT scores range from 0 to 120, with higher scores reflecting better working memory. Larger positive change scores reflect greater improvement in performance from baseline whereas greater negative change scores reflect declines in performance from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)</measure>
    <time_frame>Baseline and Day 5</time_frame>
    <description>Change in subjective cognitive functioning as measured by the FACT-Cog Perceived Cognitive Impairment scale prior to and following the intervention. Raw scores range from 0 to 72, with higher scores reflecting better perceived cognitive functioning. Larger positive change scores reflect greater improvement in subjective cognitive functioning from baseline whereas greater negative change scores reflect declines in subjective cognitive functioning from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Fatigue Symptom Inventory- SF (MFSI-SF)</measure>
    <time_frame>Baseline and Day 5</time_frame>
    <description>Change in subjective fatigue as measured by the MFSI-SF prior to and following the intervention. Raw scores range from -36 to + 144, with higher scores reflecting greater levels of fatigue. Larger positive change scores reflect greater improvement in fatigue from baseline whereas greater negative change scores reflect declines in fatigue from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Active tDCS first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS first</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.</description>
    <arm_group_label>Active tDCS first</arm_group_label>
    <arm_group_label>Sham tDCS first</arm_group_label>
    <other_name>Transcranial Direct Current Stimulation</other_name>
    <other_name>NeuroConn DC Stimulator Plus Model 0021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>Sham Transcranial direct current stimulation (tDCS)..</description>
    <arm_group_label>Active tDCS first</arm_group_label>
    <arm_group_label>Sham tDCS first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women, 18 years of age or older&#xD;
&#xD;
          -  Stage I-III breast cancer&#xD;
&#xD;
          -  Treatment Status: At least 6 months and no more than 5 years after the conclusion of&#xD;
             active breast cancer therapy, including surgery, radiation therapy and (neo)adjuvant&#xD;
             chemotherapy, if administered. NOTE: Adjuvant HER2-targeted therapy and endocrine&#xD;
             therapy may still be ongoing at the time of study enrollment.&#xD;
&#xD;
          -  Fatigue: Moderate fatigue on most days within the past week (i.e., at least 4 out of&#xD;
             the last 7 days), rated as â‰¥ 4 on a 0 (no fatigue) to 10 (worst fatigue) scale.&#xD;
&#xD;
          -  Able and willing to complete study tasks as evidenced by at least the following:&#xD;
             fluent English speaker; hearing and language comprehension; and, sufficient literacy&#xD;
             to complete study forms and questionnaires.&#xD;
&#xD;
          -  Patient understands the study regimen, its requirements, risks, and discomforts, and&#xD;
             is able and willing to sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of recurrent breast cancer at the time of enrollment.&#xD;
&#xD;
          -  Depression or anxiety as defined either by ongoing pharmacological treatment for&#xD;
             depression or anxiety or a HADS score on initial screening.&#xD;
&#xD;
          -  Dementia as assessed by a MMSE score on initial screening.&#xD;
&#xD;
          -  Known pregnancy or nursing.&#xD;
&#xD;
          -  Any of the following: diagnosis of schizophrenia or bipolar disorder made by a&#xD;
             physician, seizure disorder, pacemaker, hearing aids, any metal implanted in the head,&#xD;
             or the presence of other known current untreated causes of fatigue such as anemia or&#xD;
             untreated hypothyroidism.&#xD;
&#xD;
          -  Use of stimulant medications, sleep medications, nicotine patch, and other drugs&#xD;
             thought to interfere with tDCS efficacy for seven days prior to and during study&#xD;
             participation.&#xD;
&#xD;
          -  Use of narcotic pain medication, benzodiazepines, or illicit drugs for seven days&#xD;
             prior to and during study participation.&#xD;
&#xD;
          -  Consumption of &gt;14 alcoholic drinks per week or positive screening on the CAGE.&#xD;
&#xD;
          -  Skin conditions involving open sores on the scalp that would prevent proper&#xD;
             application of the electrodes.&#xD;
&#xD;
          -  Hairstyles that obstruct placement of the electrodes including cornrows, dreadlocks,&#xD;
             braids or other hair accessories that cannot be removed.&#xD;
&#xD;
          -  Other medical or other condition(s) that in the opinion of the investigators might&#xD;
             compromise the objectives of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-reported gender</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy D Vannorsdall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Greenspring Station</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Cognition</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Cancer-related Cognitive Impairment</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03143894/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active tDCS First</title>
          <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days. This condition is followed by an active tDCS condition after a washout.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
        </group>
        <group group_id="P2">
          <title>Sham tDCS First</title>
          <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days. This condition is followed by an active tDCS condition after a washout.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active tDCS First</title>
          <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS)..</description>
        </group>
        <group group_id="B2">
          <title>Sham tDCS First</title>
          <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS)..</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="2.5"/>
                    <measurement group_id="B2" value="69" spread="11.0"/>
                    <measurement group_id="B3" value="67.0" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change on Paced Auditory Serial Attention Test (PASAT)</title>
        <description>Change in auditory working memory as measured by the PASAT prior to and following the intervention. PASAT scores range from 0 to 120, with higher scores reflecting better working memory. Larger positive change scores reflect greater improvement in performance from baseline whereas greater negative change scores reflect declines in performance from baseline.</description>
        <time_frame>Baseline and Day 5</time_frame>
        <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
        <group_list>
          <group group_id="O1">
            <title>Active tDCS</title>
            <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS</title>
            <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
        </group_list>
        <measure>
          <title>Change on Paced Auditory Serial Attention Test (PASAT)</title>
          <description>Change in auditory working memory as measured by the PASAT prior to and following the intervention. PASAT scores range from 0 to 120, with higher scores reflecting better working memory. Larger positive change scores reflect greater improvement in performance from baseline whereas greater negative change scores reflect declines in performance from baseline.</description>
          <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
          <units>raw score change on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="5.04"/>
                    <measurement group_id="O2" value="1.83" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.47</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)</title>
        <description>Change in subjective cognitive functioning as measured by the FACT-Cog Perceived Cognitive Impairment scale prior to and following the intervention. Raw scores range from 0 to 72, with higher scores reflecting better perceived cognitive functioning. Larger positive change scores reflect greater improvement in subjective cognitive functioning from baseline whereas greater negative change scores reflect declines in subjective cognitive functioning from baseline.</description>
        <time_frame>Baseline and Day 5</time_frame>
        <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
        <group_list>
          <group group_id="O1">
            <title>Active tDCS (5 Days)</title>
            <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS (5 Days)</title>
            <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
        </group_list>
        <measure>
          <title>Change on Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)</title>
          <description>Change in subjective cognitive functioning as measured by the FACT-Cog Perceived Cognitive Impairment scale prior to and following the intervention. Raw scores range from 0 to 72, with higher scores reflecting better perceived cognitive functioning. Larger positive change scores reflect greater improvement in subjective cognitive functioning from baseline whereas greater negative change scores reflect declines in subjective cognitive functioning from baseline.</description>
          <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
          <units>raw score change on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="6.55"/>
                    <measurement group_id="O2" value="8.67" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.69</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Fatigue Symptom Inventory- SF (MFSI-SF)</title>
        <description>Change in subjective fatigue as measured by the MFSI-SF prior to and following the intervention. Raw scores range from -36 to + 144, with higher scores reflecting greater levels of fatigue. Larger positive change scores reflect greater improvement in fatigue from baseline whereas greater negative change scores reflect declines in fatigue from baseline.</description>
        <time_frame>Baseline and Day 5</time_frame>
        <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
        <group_list>
          <group group_id="O1">
            <title>Active tDCS (5 Days)</title>
            <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
          <group group_id="O2">
            <title>Sham tDCS (5 Days)</title>
            <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.&#xD;
Sham tDCS: Sham Transcranial direct current stimulation (tDCS).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Fatigue Symptom Inventory- SF (MFSI-SF)</title>
          <description>Change in subjective fatigue as measured by the MFSI-SF prior to and following the intervention. Raw scores range from -36 to + 144, with higher scores reflecting greater levels of fatigue. Larger positive change scores reflect greater improvement in fatigue from baseline whereas greater negative change scores reflect declines in fatigue from baseline.</description>
          <population>Participants who completed both active and sham conditions, allowing for calculation and comparison of change by condition.</population>
          <units>raw score change on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="6.02"/>
                    <measurement group_id="O2" value="14.83" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.36</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>47 days</time_frame>
      <desc>Adverse events related to the study intervention were recorded per the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active tDCS</title>
          <description>2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.</description>
        </group>
        <group group_id="E2">
          <title>Sham tDCS</title>
          <description>Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days.&#xD;
tDCS: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tracy Vannorsdall, PhD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-3701</phone>
      <email>TVannor1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

